Get started
Author

Ling Cai

Observed institution: AstraZeneca (United States)
ORCID: 0009-0003-5086-3509
Observed ORCID: 0009-0003-5086-3509
OpenAlex ID: A5143463587
Supplementary Figure S2 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Supplementary Figure S1 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Supplementary Tables S1-S11 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Data from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Supplementary Figure S3 from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Supplementary Methods from Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al.
Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)
2026 · Ferdinandos Skoulidis, Salma K. Jabbour, et al. · Clinical Cancer Research
Works count: 7
Citation count:
H-index:
I10-index:
Year
Topic
Type